ライフサイエンスコーパス: intravaginal

1 Distinct differences were observed in intravaginal 50% infectious doses and in challenge infec

2 Here, we show for the first time that intravaginal administration with nanoparticles of poly(l

3 ompartmentalized, being induced primarily by intravaginal administration.

4 d waned, the 3 animals became infected after intravaginal and/or intravenous rechallenge.

5 Intravaginal antigenic challenge represents a novel appr

6 vaginal lavage (CVL) samples collected after intravaginal application of 0.5% PRO 2000 gel (Indevus).

7 Animals received a single intravaginal application of 15 microL of a 10% PRO 2000

8 Intravaginal application of siRNAs targeting the HSV-2 U

9 retains substantial antiviral activity after intravaginal application.

10 erated in the cervicovaginal mucosa upon HPV intravaginal boost.

11 from symptomatic infection following a live intravaginal Candida challenge had increased VEC anti-Ca

12 d protection against disease and death after intravaginal challenge and markedly lowered the titers o

13 body were completely resistant to repetitive intravaginal challenge by a heterosexually transmitted f

14 ing Ad5gp vaccination were more resistant to intravaginal challenge by recombinant vaccinia virus exp

15 rred significantly higher protection against intravaginal challenge infection by the HSV-2 186 strain

16 Similar to previous findings, intravaginal challenge of C57BL/6 mice with hypha-defect

17 V, we developed an animal model based on the intravaginal challenge of female rhesus monkeys with SHI

18 Consistent with these findings, intravaginal challenge of macaques with SIV(mac251) prei

19 In contrast, fungal burden induced by intravaginal challenge of nearly all (97%) isolates was

20 Upon intravaginal challenge of these orally immunized mice wi

21 ct HIV-1 infection after HIV-Du151.2env-NLuc intravaginal challenge was increased ~4-fold in hCD4/R5/

22 O 2000 vaginal gel formulation 20 s prior to intravaginal challenge with 4.0 log10 pfu of herpes simp

23 ed in enhanced protection against a low-dose intravaginal challenge with a heterologous strain of SIV

24 eby vaginal immunity could be detected after intravaginal challenge with Candida antigen.

25 e to the SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239.

26 as sufficiently potent to protect against an intravaginal challenge with recombinant vaccinia virus e

27 -mediated control of viral replication after intravaginal challenge with SIVmac239.

28 Upon intravaginal challenge with SIVmac251, both persistently

29 Using a stringent repeated low-dose intravaginal challenge with the highly pathogenic SIVmac

30 cervicovaginal viral titers 1,000-fold after intravaginal challenge with vaccinia virus expressing th

31 wild-type, but not FcRn knockout, mice after intravaginal challenge with virulent HSV-2 186.

32 rus by delivery of 17beta-estradiol prior to intravaginal challenge with wild-type GBS 874391.

33 rom local or systemic herpetic disease after intravaginal challenge with wild-type HSV-1 or HSV-2.

34 CD4(+) and CD8(+) T cells prior to secondary intravaginal challenge, we identified lymphocyte populat

35 ing immunization and in vaginal washes after intravaginal challenge.

36 hanced protection against repeated low-dose, intravaginal challenges with heterologous SIVsmE660 in a

37 infection following 12 consecutive low-dose intravaginal challenges with simian-HIV strain SF162P3,

38 cine control animal, resisted two successive intravaginal challenges with SIV(mac251) and failed to s

39 rom transmission following repeated low-dose intravaginal challenges with SIVmac251.

40 In multivariable analysis, only intravaginal cleansing (practiced by 20.9%) was associat

41 ts and 100% of Ugandan participants reported intravaginal cleansing during the six week study period.

42 of sexual activity, and it is possible that intravaginal cleansing is a marker for unreported sexual

43 While intravaginal cleansing was commonly practiced in both co

44 d sexual debut, and this was associated with intravaginal cleansing.

45 in evidence of BV were randomized to receive intravaginal clindamycin or metronidazole.

46 Mice received 14 daily intravaginal doses of nonoxynol-9, PRO 2000, or placebo

47 arized cultures and testing whether repeated intravaginal dosing potentiates the susceptibility of mi

48 Intravaginal drug delivery can elicit a local effect, or

49 There are a number of emerging areas in intravaginal drug delivery, but the vagina is a challeng

50 followed by an overview of polymeric gels in intravaginal drug delivery.

51 The primary endpoint was intravaginal ejaculatory latency time (IELT) measured by

52 The intravaginal ejaculatory latency time remains the primar

53 Postexposure prophylaxis (PEP) after intravaginal exposure to human immunodeficiency virus (H

54 n vitro could protect macaques from repeated intravaginal exposure to low doses of a simian immunodef

55 lymph nodes that rapidly expanded following intravaginal exposure to SIV(mac251.) HPV PsV-based vehi

56 V enters the vaginal mucosa within 60 min of intravaginal exposure, infecting primarily intraepitheli

57 Rechallenge with two sequential SIVmac251 intravaginal exposures again resulted in partial protect

58 Although intravaginal formulations of topical azole antifungals a

59 unding by indication, pregnancies exposed to intravaginal formulations of topical azoles were used as

60 The sensorial properties of intravaginal gels, and how these relate to user complian

61 inhibition of virus lesion development in an intravaginal guinea pig herpes simplex virus-2 assay.

62 -1) infections are acquired by women through intravaginal HIV exposure.

63 ital tract renders these mice susceptible to intravaginal HIV infection.

64 A single low-dose intravaginal HIV-1 challenge of humanized DRAG mice resu

65 no HSPC injection, were also susceptible to intravaginal HIV.

66 Intravaginal HPV prime/boost reduced cervicovaginal vira

67 ization with ALVAC-SIV vaccines, followed by intravaginal HPV-PsV-SIV/gp120 boosting, expanded and/or

68 y and severity of herpetic lesions following intravaginal HSV challenge.

69 he burden of latent infection resulting from intravaginal HSV-2 challenge, and a nucleic acid vaccine

70 After intravaginal HSV-2 challenge, the mock and UL19/UL47 ade

71 d vaginal washing virus titers were measured intravaginal HSV-2 challenge.

72 uccumb to lethal infection (p < 0.005) after intravaginal HSV-2 challenge.

73 ated in the LT beta-deficient mice following intravaginal HSV-2 infection even in the absence of the

74 y was to develop a nonhuman primate model of intravaginal human immunodeficiency virus (HIV) transmis

75 following intranasal (IN), sublingual (SL), intravaginal (I.Vag) and intrarectal (IR) administration

76 uate mucosal vaccines for protection against intravaginal (i.vag.) transmission in macaque models of

77 st Candida vaginal infection, established by intravaginal (i.vg.) inoculation of yeast cells in mice

78 the female mouse cervicovaginal mucosa after intravaginal immunization with human papillomavirus vect

79 viducts at various times following a primary intravaginal infection and after a challenge infection.

80 ce appeared to be as resistant to chlamydial intravaginal infection as wild-type mice based on the nu

81 but which is now pathogenic and establishes intravaginal infection efficiently.

82 protected humanized mice against repetitive intravaginal infection in a dose-dependent manner.

83 Our previous studies revealed that intravaginal infection of mice with a plasmid-deficient

84 Intravaginal infection with Chlamydia muridarum in mice

85 ng wild-type mice (C5(+/+)) did so following intravaginal infection with Chlamydia muridarum.

86 After intravaginal infection with Chlamydia, CCR7-deficient mi

87 Following intravaginal infection with HSV type 2, activated dendri

88 in the genital tract as early as 12 h after intravaginal infection with MoPn.

89 Intravaginal infection with plasmid-competent but not pl

90 s were detected in vaginal tissues following intravaginal infection with T. vaginalis but were not se

91 These intravaginal infections of the mouse do not ascend effic

92 wever, T/F Envs derived from intrarectal and intravaginal infections were not different.

93 cells, but not CD4 cells, were reduced after intravaginal injection of complement-fixing anti-Thy-1.2

94 C. muridarum infection in mice following an intravaginal inoculation and confirmed the rapid ascent

95 y of upper genital tract pathology following intravaginal inoculation into mice compared to the paren

96 by repeated negative cultures) occurs after intravaginal inoculation of a low dose of pathogenic SIV

97 However, intravaginal inoculation of animals with these two SHIVs

98 UL24-betagluc was not virulent after intravaginal inoculation of BALB/c mice in that all inoc

99 Nevertheless, intravaginal inoculation of C. albicans into both specie

100 Intravaginal inoculation of cats with feline immunodefic

101 Intravaginal inoculation of guinea pigs with UL24-betagl

102 Intravaginal inoculation of HSV-2 led to a rapid recruit

103 Intravaginal inoculation of mice with an attenuated stra

104 Intravaginal inoculation of mice with C. albicans strain

105 Thus, transient viremia following intravaginal inoculation of pathogenic SIV is associated

106 r SHIV will produce systemic infection after intravaginal inoculation of rhesus macaques.

107 data from eight (donor) monkeys infected by intravaginal inoculation of SIVmac251, three monkeys inf

108 Intravaginal inoculation of the TC0668 null mutant into

109 of nectin-1 to mediate viral entry following intravaginal inoculation was examined in a mouse model o

110 mouse model of ascending infection following intravaginal inoculation with a strain of Chlamydia trac

111 A single atraumatic intravaginal inoculation with a T-cell-tropic molecular

112 n spinal cords of mice up to 10 months after intravaginal inoculation with a thymidine kinase-deficie

113 PMNs at the vaginal mucosal surface prior to intravaginal inoculation with an attenuated HSV-2 strain

114 the murine vaginal mucosa within 24 h after intravaginal inoculation with an attenuated strain of he

115 y intraperitoneal injection before and after intravaginal inoculation with C. trachomatis.

116 ravenous inoculation predicts the outcome of intravaginal inoculation with each virus.

117 l 5 strains developed hydrosalpinx following intravaginal inoculation with plasmid-competent, but not

118 Following intravaginal inoculation with primarily Opa- gonococci,

119 either progesterone or estrogen followed by intravaginal inoculation with SIVmac.

120 Intravaginal inoculation with T cell-tropic molecular cl

121 Following intravaginal inoculation, a C. muridarum strain deficien

122 cytokine production in the oviduct than the intravaginal inoculation, suggesting that the oviduct in

123 iruses will produce systemic infection after intravaginal inoculation, the level to which a virus rep

124 positive time point after low- and high-dose intravaginal inoculation.

125 nous inoculation does predict the outcome of intravaginal inoculation.

126 virus to initiate a systemic infection after intravaginal inoculation.

127 n the mouse lower genital tract following an intravaginal inoculation.

128 ability to infect rhesus macaques following intravaginal inoculation.

129 tion of the gastrointestinal tract following intravaginal inoculation.

130 been infected by exposure to at least three intravaginal inoculations of SHIV 89.6.

131 It has previously been shown that 12 intravaginal inoculations with SIVmac1A11 resulted in in

132 In both countries, intravaginal insertion (e.g. with herbs) was less common

133 level of transport was evident at 4 hr after intravaginal instillation, and transport peaked at about

134 ) and histamine were increased 16-18 h after intravaginal introduction of Candida skin test antigen.

135 ted from infection or clinical disease after intravaginal (IVAG) challenge with pathogenic SIVmac239.

136 Here we evaluated intravaginal (ivag) genetic immunization of C57BL/6 mice

137 intramuscular (i.m.), intranasal (i.n.), or intravaginal (IVAG) immunization with VEE/SIN-Gag and an

138 Intravaginal (IVAG) inoculation of wild-type herpes simp

139 e (10(3) 50% tissue culture infective doses) intravaginal (IVAG) inoculations with simian immunodefic

140 In the present study, an intravaginal live Candida challenge in healthy adult wom

141 rasound-guided intrauterine LPS injection or intravaginal LPS administration could induce PTB by stim

142 Intravaginal LPS administration did not stimulate PTB.

143 en from the United States and Kenya received intravaginal metronidazole (750 mg) plus miconazole (200

144 nya with a recent vaginal infection received intravaginal metronidazole 750 mg plus miconazole 200 mg

145 Bacterial vaginosis was treated with intravaginal metronidazole gel (0.75%), 37.5 mg nightly

146 Monthly treatment with intravaginal metronidazole plus miconazole reduced the p

147 t evidence for the protective efficacy of an intravaginal microbicide/vaccine or microbivac platform

148 The effect on normal vaginal flora of three intravaginal microbicides potentially active against hum

149 C. sordellii infections were associated with intravaginal misoprostol administration, suggesting that

150 levant placebo, or no treatment, followed by intravaginal N. gonorrhoeae challenge.

151 After intravaginal or intracranial inoculation of adult mice,

152 gD1) provided 100% protection against lethal intravaginal or skin challenges and prevented latency.

153 n strategies, fluid management, medications, intravaginal pessaries, intravesical injection of botuli

154 were studied to determine whether the use of intravaginal practices (cleaning with the fingers, wipin

155 Intravaginal practices (IVP) are highly prevalent in sub

156 depot medroxyprogesterone acetate (DMPA) and intravaginal practices may be associated with human immu

157 This study evaluated the effect of DMPA and intravaginal practices on the genital proteome and micro

158 ace-to-face interview on sexual behavior and intravaginal practices, and a nurse-assisted self-admini

159 An HPV intravaginal prime/boost with different HPV serotypes in

160 une mice and could be detected by 24 h after intravaginal reinoculation.

161 ant reductions in the extent and duration of intravaginal replication of challenge HSV-1 and HSV-2 co

162 atrix, hydrophilic polyether urethane (HPEU) intravaginal ring (IVR) for sustained delivery of the an

163 Here, we describe a novel core-matrix intravaginal ring (IVR), the MZCL IVR, which effectively

164 Intravaginal ring technology is generally limited to rel

165 ptive transdermal patch, a hormone-releasing intravaginal ring, new formulations of pills, and a new

166 Intravaginal rings (IVRs) may improve efficacy by provid

167 sumed to be low cost and highly efficacious; intravaginal rings targeted to sex workers; and vaccines

168 o the extent assumed, emphasis on oral PrEP, intravaginal rings, and long-acting antiretroviral drugs

169 w interventions in the medium term (offering intravaginal rings, long-acting injectable antiretrovira

170 iversity of drugs that can be delivered from intravaginal rings, we designed an IVR that contains a d

171 al medication, the transdermal patch and the intravaginal route are starting to be used in clinical p

172 inoculated by either the intravenous or the intravaginal route.

173 months later with pathogenic SHIVKU-1 by the intravaginal route.

174 on against virulent SHIV administered by the intravaginal route.

175 e animal infectious dose of the virus by the intravaginal route.

176 us (SHIV(KU-1)) to inoculate macaques by the intravaginal route.

177 h cell-free SHIV-E-CAR by the intravenous or intravaginal route; virus replicated in these animals bu

178 infected with SIVagm by both intrarectal and intravaginal routes, (ii) susceptibility to infection is

179 monkeys efficiently by both intrarectal and intravaginal routes, replicated to high levels during ac

180 three rhesus macaques by the intravenous and intravaginal routes, respectively.

181 ious routes of infection, including oral and intravaginal routes, to mimic natural routes of transmis

182 s type 2 (HSV-2) in mice can be inhibited by intravaginal siRNA application.

183 hat transpire from hours to a few days after intravaginal SIV exposure through week 4 to provide a fr

184 cated in draining lymph nodes within 18 h of intravaginal SIV exposure.

185 ne-treated animals became infected following intravaginal SIV inoculation.

186 d animals, except one, became infected after intravaginal SIV(mac251) low-dose challenge.

187 uximab (anti-CD20) 28 days and 7 days before intravaginal SIVmac239 inoculation and every 21 days the

188 immunization strategies with intrarectal and intravaginal SIVsmE660 challenge of rhesus macaques.

189 PCR testing of wet and dry transported intravaginal swabs to detect chlamydia and gonorrhea inf

190 We assessed the accuracy of intravaginal swabs transported by mail in a wet versus a

191 To evaluate safety of intravaginal testosterone cream (IVT) or an estradiol-re

192 To test the feasibility of localized intravaginal therapy directed to neighboring lymph nodes

193 membrane-bound form, induced circulating and intravaginal-tissue-resident memory CD8(+) T cells that

194 It has different etiology than intravaginal torsion, which appears later in life.

195 ficiency virus (SIV)-rhesus macaque model of intravaginal transmission of human immunodeficiency viru

196 ied topically prior to SIV(mac251) prevented intravaginal transmission of virus compared to controls

197 cyte loss in the SIV/rhesus macaque model of intravaginal transmission.

198 es associated with SIVsmE660 intrarectal and intravaginal transmissions in vaccinated and unvaccinate

199 ssing the toxicity of compounds intended for intravaginal use.

200 This study describes intravaginal vaccination with a nonreplicating HPV-based

201 Intravaginal vaccination with HPV-PsVs expressing SIV ge

202 Intravaginal vaccination with HPV16, HPV45, and HPV58 Ps

203 xposure to BCD and SIV(mac251) in subsequent intravaginal virus challenges (P = 0.63), despite the po